<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Leal Therapeutics</title>
    <link>https://www.biospace.com/employer/3076356/leal-therapeutics</link>
    <description>Leal Therapeutics</description>
    <language>en-US</language>
    <lastBuildDate>Thu, 31 Oct 2024 09:43:48 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076356/leal-therapeutics.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Leal Therapeutics Announces $45 Million Financing to Progress Novel Therapies for Patients with Major Neurodegenerative and Neuropsychiatric Disorders</title>
      <link>https://www.biospace.com/press-releases/leal-therapeutics-announces-45-million-financing-to-progress-novel-therapies-for-patients-with-major-neurodegenerative-and-neuropsychiatric-disorders</link>
      <description />
      <pubDate>Thu, 31 Oct 2024 09:43:48 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/leal-therapeutics-announces-45-million-financing-to-progress-novel-therapies-for-patients-with-major-neurodegenerative-and-neuropsychiatric-disorders</guid>
    </item>
    <item>
      <title>Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update</title>
      <link>https://www.biospace.com/press-releases/leal-therapeutics-announces-executive-leadership-appointments-and-provides-business-update</link>
      <description />
      <pubDate>Tue, 14 Apr 2026 04:33:37 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/leal-therapeutics-announces-executive-leadership-appointments-and-provides-business-update</guid>
    </item>
    <item>
      <title>Leal Therapeutics Doses First Patient in NeurALS Phase 1/2 Trial of LTX-002 for Amyotrophic Lateral Sclerosis (ALS)</title>
      <link>https://www.biospace.com/press-releases/leal-therapeutics-doses-first-patient-in-neurals-phase-1-2-trial-of-ltx-002-for-amyotrophic-lateral-sclerosis-als</link>
      <description />
      <pubDate>Wed, 24 Jun 2026 03:37:01 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/leal-therapeutics-doses-first-patient-in-neurals-phase-1-2-trial-of-ltx-002-for-amyotrophic-lateral-sclerosis-als</guid>
    </item>
    <item>
      <title>Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia</title>
      <link>https://www.biospace.com/press-releases/leal-therapeutics-announces-30-million-series-a-extension-and-initiation-of-phase-1b-2a-clinical-trial-of-ltx-001-in-schizophrenia</link>
      <description />
      <pubDate>Tue, 18 Aug 2026 01:25:25 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/leal-therapeutics-announces-30-million-series-a-extension-and-initiation-of-phase-1b-2a-clinical-trial-of-ltx-001-in-schizophrenia</guid>
    </item>
  </channel>
</rss>
